ArticleOncology letters2017

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, suppresses CXCL5 and SDF-1 and does not accelerate intestinal neoplasia formation in

Kaori Fujiwara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.